Progress in migraine: treatment with dihydroergotamine-retard.
A group of 40 patients suffering from migraine underwent dihydroergotamine-retard therapy for a period of five months after a 30-day pre-treatment period. They had previously been treated with other medications but results were not relevant. Drug effectiveness was evaluated by means of Pain Total Index, number of attacks, analgesic consumption and number of awakenings with headache. The results show a significant difference between the observation period and the treatment phase, with relevant therapeutic success. Only moderate side-effects were observed.
D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D004087:Dihydroergotamine